Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis

Toxins

Emmanouil V. Dermitzakis¹  George S. Vlachos²  Michail Vikelis²  Andreas A. Argyriou³ 

[1] Department of Neurology, “Geniki Kliniki” Euromedica, 54645 Thessaloniki, Greece;Headache Clinic, Mediterraneo Hospital, 16675 Glyfada, Greece;Neurology Department of the “Agios Andreas” State General Hospital of Patras, Headache Outpatient Clinic, 26335 Patras, Greece;

关键词: OnabotulinumtoxinA;    chronic migraine;    efficacy;    tolerability/safety;    circadian time;   

DOI  :  10.3390/toxins14050296

来源: DOAJ

【 摘 要 】

We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who completed three consecutive cycles of treatment, according to the standard PREEMPT paradigm. Participants were classified to those scheduled to be treated in the morning hours from 8:00 to 12:00 (AM) or afternoon hours from 13:00 to 18:00 (PM). We then assessed and compared between groups the changes from baseline (T0—trimester before BoNTA’s first administration) to the period after its third administration (T3) in the following efficacy outcomes: (i) mean number of headache days/month, (ii) mean number of days/month with peak headache intensity of >4/10, (iii) mean number of days/month with consumption of any abortive treatment. Safety–tolerability was also compared between groups. Results: A total of 50 AM and 50 PM-treated patients were evaluated. The within-group analysis in both groups showed a significant decrease in all efficacy variables between T0 and T3. However, the between-group comparisons of all BoNTA-related efficacy outcomes at T3 vs. T0 documented comparable improvements between AM vs. PM-treated patients. Safety/tolerability was also similar between groups. Conclusions: We were not able to identify significant differences between patients treated in the AM vs. PM, so as to demonstrate that the circadian time of administration should be considered before initiating BoNTA in CM patients.

【 授权许可】

Unknown